In a note released Wednesday, Morgan Stanley analyst David Risinger upgraded AbbVie ABBV from Equal-weight to Overweight and raised the price target from $47 to $60.
Risinger made it clear that the primary reason for this upgrade is AbbVie's hepatitis-C cure regimen which is set to launch in late 2014. With the launch of the hepatitis-C cure, Risinger expects AbbVie will be able to capture a larger portion of the available market (over 33 percent) in 2015. Based on this Risinger has significantly raised his EPS estimates for 2014 - 2016 to a level "well above consensus".
For 2014 he increased his estimate four percent from $3.12 to $3.23 ($3.13 consensus) , 37 percent for 2015 from $3.60 to $4.82 ($3.72 consensus) and 30 percent for 2016 from $3.83 to $4.98 ($4.23 consensus).
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in